NCT06958289 Cryoneurolysis for Spasticity Treatment: Long-term Clinical Outcomes and Mechanisms in the Central Nervous System
| NCT ID | NCT06958289 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sue Peters |
| Condition | Spasticity as Sequela of Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 25 participants |
| Start Date | 2025-08-01 |
| Primary Completion | 2027-12-01 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Spasticity can make regular daily activities difficult or impossible. Cryoneurolysis is a new technique to treat spasticity that is currently being tested. For this technique, a needle is inserted alongside a nerve implicated in spasticity. The needle then freezes and causes the nerve to break down. The nerve breaking down seems to provide relief for spasticity. The investigators are interested in testing the long-term effects of cryoneurolysis on the function of the brain over six months after treatment. The investigators are testing the brain's function using transcranial magnetic stimulation (TMS) which involves a magnet activating specific parts of the brain that cause muscles to fire; magnetic resonance imaging (MRI) which uses to examine brain structure; functional near-infrared spectroscopy (fNIRS) to examine brain function. The investigators believe that there will be a change in these measures that are related to the long-lasting effects of cryoneurolysis. Cryoneurolysis is not a part of standard care after stroke but is approved in Canada for patients. It has been used extensively in the past for treating pain. TMS is a way of studying how the brain sends signals to muscles to make movement. During these sessions, a researcher will use a magnet to turn on specific neurons in the brain that will cause muscles to contract. The investigators can study the way eyes and muscles respond to better understand how the brain is sending information about moving the body to the muscles. FNIRS is a new way of studying how the brain works. During these sessions, a researcher will fit the participant with a cap that has several lights on it. The light travels through hair, scalp, and skull where it interacts with blood in the brain. By studying the changes in the colour of the blood in the brain, researchers can understand which parts of the brain are active during specific tasks. Magnetic Resonance Imaging (MRI) involves a powerful magnet that takes very detailed pictures of the brain. These images help the investigators to understand how a stroke is related to spasticity. Also, these images are helpful to make the stimulation with TMS more accurate. Study participation will require five visits to the Parkwood Institute Main Building and one visit to St. Joseph's Hospital. The entire study will take place over roughly six months. The investigators are recruiting 25 people with stroke who are eligible for cryoneurolysis to participate in the study.
Eligibility Criteria
Inclusion Criteria: * have increased range of motion or reduced spasticity with diagnostic nerve block, * have no undesired loss of function with a diagnostic nerve block, * score 2 or higher in the Modified Ashworth scale, * have at least flickers of movement in the upper extremity, * have not received botulinum-A neurotoxin within the past 3 months, * if on anti-spastic medication, maintaining anti-spastic medications on a stable schedule over the course of the follow up period, and * they can understand and follow instructions in English. Exclusion Criteria: * have contraindications to TMS (i.e., history of seizure, pregnancy) or 3T MRI (i.e., certain metallic implants), * are unable to provide informed consent (i.e., severe cognitive impairment), * receive any toxin injections for spasticity (Botulinum-A Toxin or equivalent) within 3 months of initial baseline assessments or at any time over the course of the follow-up period. * Have previously undergone any nerve-specific interven
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.